Global Tyrosine Kinase JAK Inhibitors Sales Market Report 2021
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion in 2017 is about 37%.
Market Analysis and Insights: Global Tyrosine Kinase JAK Inhibitors Market
The global Tyrosine Kinase JAK Inhibitors market was valued at US$ 24110 in 2020 and will reach US$ 191900 million by the end of 2027, growing at a CAGR of 41.3% during 2022-2027.
Global Tyrosine Kinase JAK Inhibitors Scope and Market Size
The global Tyrosine Kinase JAK Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tyrosine Kinase JAK Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Tofacitinib
Ruxolitinib
Baricitinib
Segment by Application
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
Others
The Tyrosine Kinase JAK Inhibitors market is analysed and market size information is provided by regions (countries). Segment by Application, the Tyrosine Kinase JAK Inhibitors market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion in 2017 is about 37%.
Market Analysis and Insights: Global Tyrosine Kinase JAK Inhibitors Market
The global Tyrosine Kinase JAK Inhibitors market was valued at US$ 24110 in 2020 and will reach US$ 191900 million by the end of 2027, growing at a CAGR of 41.3% during 2022-2027.
Global Tyrosine Kinase JAK Inhibitors Scope and Market Size
The global Tyrosine Kinase JAK Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tyrosine Kinase JAK Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Tofacitinib
Ruxolitinib
Baricitinib
Segment by Application
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
Others
The Tyrosine Kinase JAK Inhibitors market is analysed and market size information is provided by regions (countries). Segment by Application, the Tyrosine Kinase JAK Inhibitors market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
